The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer

  • Lee, Ji Hyun (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Kim, Sung-Hyun (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Oh, Sung Yong (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Lee, Suee (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Lee, Hojin (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Lee, Hye Jung (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Kim, Hyo-Jin (Department of Internal Medicine, Dong-A University College of Medicine)
  • Published : 2013.05.01
⟨ Previous Next ⟩

Abstract

Background/Aims: To determine the efficacy and toxicity of docetaxel as a thirdline therapy for patients with relapsed gastric cancer who have undergone modified oxaliplatin-fluorouracil (m-FOLFOX)-4 and modified irinotecan-fluorouracil (m-FOLFIRI) regimens. Methods: We analyzed 33 patients who had been histologically diagnosed with adenocarcinoma of the stomach and who had progressed after m-FOLFOX-4 and m-FOLFIRI regimens. Patients were treated with cycles of 75 mg/m2 docetaxel on day 1 every 3 weeks. Results: The median age of the patients was 56.0 years (range, 31.0 to 74.0), and 73% of the patients (24/33) had an Eastern Cooperative Oncology Group performance status of 0 or 1. All patients were evaluated in terms of tumor response: five (15%), nine (27%), and 19 (58%) patients experienced a partial response, stable disease, and progressive disease, respectively. The median time to progression was 2.1 months (95% confidence interval [CI], 1.63 to 2.58), and overall survival was 4.7 months (95% CI, 3.20 to 6.20), from the start of the docetaxel regimen. Assessing patients' toxicity profiles, the median number of cycles was 2.0 (range, 1.0 to 12.0). The major hematologic toxicities included grade 3 to 4 neutropenia (19/33, 58%), grade 3 to 4 thrombocytopenia (2/33, 6%), and grade 3 to 4 anemia (5/33, 15%). Neutropenic fever developed in three patients (3/33, 9%). The nonhematological toxicities were nausea and vomiting (10/33, 30%), abdominal pain (4/33, 12%), skin rash (1/33, 3%), and fluid retention (3/33, 9%). Conclusions: Docetaxel is a feasible third-line therapy regimen for patients with advanced gastric cancer after m-FOLFIRI and m-FOLFOX-4 regimens.

Keywords

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. https://doi.org/10.3322/canjclin.55.2.74
  2. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-190. https://doi.org/10.1093/oxfordjournals.annonc.a058778
  3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. https://doi.org/10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
  4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of f luorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591. https://doi.org/10.1038/bjc.1995.114
  5. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A 2001;98:5312-5316. https://doi.org/10.1073/pnas.051309398
  6. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999;10:947-959. https://doi.org/10.1091/mbc.10.4.947
  7. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park) 2002;16(6 Suppl 6):89-96.
  8. Bang YJ, Kang WK, Kang YK, et al. Docetaxel 75 mg/ m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 2002;32:248-254. https://doi.org/10.1093/jjco/hyf057
  9. Giuliani F, Gebbia V, De Vita F, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res 2003;23(5b):4219-4222.
  10. Graziano F, Catalano V, Baldelli AM, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000;11:1263-1266. https://doi.org/10.1023/A:1008373814453
  11. Lee JL, Ryu MH, Chang HM, et al. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 2008;61:631-637. https://doi.org/10.1007/s00280-007-0516-6
  12. Taguchi T, Sakata Y, Kanamaru R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho 1998;25:1915-1924.
  13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. https://doi.org/10.1093/jnci/92.3.205
  14. Kim BG, Oh SY, Kwon HC, et al. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer. Am J Clin Oncol 2010;33:246-250.
  15. Kim SG, Oh SY, Kwon HC, et al. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol 2007;37:744-749. https://doi.org/10.1093/jjco/hym103
  16. Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol 2007;46:336-341. https://doi.org/10.1080/02841860600791483
  17. Suh SH, Kwon HC, Jo JH, et al. Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer. Cancer Res Treat 2005;37:279-283. https://doi.org/10.4143/crt.2005.37.5.279
  18. Moon YW, Rha SY, Jeung HC, et al. Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother Pharmacol 2010;66:797-805. https://doi.org/10.1007/s00280-010-1295-z
  19. Shimoyama R, Yasui H, Boku N, et al. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to f luorouracil, irinotecan, and cisplatin. Gastric Cancer 2009;12:206-211. https://doi.org/10.1007/s10120-009-0524-9
  20. Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-1518. https://doi.org/10.1200/JCO.2011.39.4585

Cited by

  1. Design of precise third-line therapy for gastric cancer: target or chemotherpy? vol.28, pp.3, 2013, https://doi.org/10.3904/kjim.2013.28.3.297
  2. Chemotherapy beyond second-line in advanced gastric cancer vol.21, pp.29, 2013, https://doi.org/10.3748/wjg.v21.i29.8811
  3. Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma vol.8, pp.4, 2013, https://doi.org/10.1177/1756283x15585468
  4. Advanced gastric cancer: is there an optimal chemotherapy regimen? vol.2, pp.2, 2013, https://doi.org/10.1080/23809000.2017.1313683
  5. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? vol.2, pp.3, 2013, https://doi.org/10.1136/esmoopen-2017-000206
  6. Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis vol.96, pp.24, 2013, https://doi.org/10.1097/md.0000000000006884
  7. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy vol.22, pp.12, 2013, https://doi.org/10.1634/theoncologist.2017-0158
  8. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study vol.13, pp.6, 2013, https://doi.org/10.1371/journal.pone.0198544
  9. The role of third-line chemotherapy in recurrent or metastatic gastric cancer : A cohort study with propensity score matching analysis vol.97, pp.39, 2013, https://doi.org/10.1097/md.0000000000012588
  10. Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study vol.12, pp.None, 2019, https://doi.org/10.2147/ott.s193801